Mission in a Minute

World Preeclampsia Day: May 22

Preeclampsia is a serious pregnancy complication that impacts hundreds of thousands of women each year. It’s often characterized by a rapid rise in blood pressure, and, although the cause of preeclampsia remains unclear, its severe impact on maternal and fetal health is undeniable.

Through our advanced diagnostics, Thermo Fisher is enabling clinicians to more accurately diagnose and treat this condition and ultimately help improve outcomes for both mother and child.

In May 2023, we launched the first blood test cleared by the U.S. Food and Drug Administration to help determine a pregnant woman’s risk of developing severe preeclampsia, setting a new standard in maternal care.

With proven results from the largest U.S. prospective study examining the biomarkers for preeclampsia risk prediction to date, the test can measure the risk of adverse outcomes and help physicians determine the best path for clinical management.

On World Preeclampsia Day, Thermo Fisher joins a global community in raising awareness for this condition and celebrates the scientists who made this innovative test possible.

 

Learn more about how this test and our full prenatal screening portfolio can help doctors confidently make better care decisions, give mothers and families peace of mind, and, ultimately, help improve global maternal health. 

Back to top